Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Current Assets (2020 - 2025)

Historic Current Assets for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $990.7 million.

  • Apellis Pharmaceuticals' Current Assets rose 1880.08% to $990.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $990.7 million, marking a year-over-year increase of 1880.08%. This contributed to the annual value of $789.0 million for FY2024, which is 295.21% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Current Assets stood at $990.7 million for Q3 2025, which was up 1880.08% from $755.6 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year Current Assets high stood at $1.1 billion for Q1 2022, and its period low was $475.4 million during Q3 2021.
  • Moreover, its 5-year median value for Current Assets was $811.4 million (2024), whereas its average is $816.9 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Current Assets plummeted by 3595.64% in 2021 and then skyrocketed by 7498.73% in 2022.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Current Assets stood at $824.0 million in 2021, then dropped by 12.68% to $719.5 million in 2022, then grew by 6.51% to $766.3 million in 2023, then rose by 2.95% to $789.0 million in 2024, then increased by 25.57% to $990.7 million in 2025.
  • Its last three reported values are $990.7 million in Q3 2025, $755.6 million for Q2 2025, and $727.7 million during Q1 2025.